Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Huadong Medicine Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Huadong Medicine kazanç ve gelirin sırasıyla yıllık 13.5% ve 8.1% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 13.5% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 16.4% olacağı tahmin edilmektedir.

Anahtar bilgiler

13.5%

Kazanç büyüme oranı

13.5%

EPS büyüme oranı

Healthcare kazanç büyümesi	21.2%
Gelir büyüme oranı	8.1%
Gelecekteki özkaynak getirisi	16.4%
Analist kapsamı	Good
Son güncelleme	23 Aug 2024

Gelecekteki son büyüme güncellemeleri

Huadong Medicine Co., Ltd (SZSE:000963) Yearly Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Apr 21

Recent updates

There Are Reasons To Feel Uneasy About Huadong Medicine's (SZSE:000963) Returns On Capital

Sep 23

Earnings Working Against Huadong Medicine Co., Ltd's (SZSE:000963) Share Price

Aug 05

Huadong Medicine (SZSE:000963) Seems To Use Debt Rather Sparingly

Jun 28

There Are Reasons To Feel Uneasy About Huadong Medicine's (SZSE:000963) Returns On Capital

Jun 10

Huadong Medicine Co., Ltd (SZSE:000963) Yearly Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Apr 21

Market Cool On Huadong Medicine Co., Ltd's (SZSE:000963) Earnings

Apr 08

Is Huadong Medicine (SZSE:000963) A Risky Investment?

Mar 16

Kazanç ve Gelir Büyüme Tahminleri

SZSE:000963 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (CNY Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	51,181	4,364	3,217	4,802	12
12/31/2025	47,674	3,901	2,785	4,275	15
12/31/2024	43,928	3,323	2,559	4,109	15
6/30/2024	41,204	3,101	2,516	4,183	N/A
3/31/2024	40,920	2,946	2,010	3,691	N/A
12/31/2023	40,624	2,839	2,323	3,929	N/A
9/30/2023	40,251	2,707	1,996	3,311	N/A
6/30/2023	39,902	2,592	2,932	4,119	N/A
3/31/2023	38,897	2,550	998	2,396	N/A
1/1/2023	37,715	2,499	1,189	2,382	N/A
9/30/2022	36,494	2,388	1,266	2,384	N/A
6/30/2022	35,582	2,342	696	1,715	N/A
3/31/2022	34,599	2,248	1,897	2,607	N/A
1/1/2022	34,563	2,302	2,351	3,170	N/A
9/30/2021	34,110	2,324	2,468	3,616	N/A
6/30/2021	34,202	2,389	2,540	3,894	N/A
3/31/2021	33,982	2,431	1,986	3,495	N/A
12/31/2020	33,683	2,820	1,938	3,411	N/A
9/30/2020	33,319	2,991	1,669	2,994	N/A
6/30/2020	33,858	2,948	1,036	2,294	N/A
3/31/2020	34,339	3,053	1,345	2,654	N/A
12/31/2019	35,446	2,813	648	2,002	N/A
9/30/2019	35,087	2,671	469	1,537	N/A
6/30/2019	33,587	2,570	878	1,932	N/A
3/31/2019	32,532	2,515	1,225	2,163	N/A
12/31/2018	30,663	2,267	1,163	2,039	N/A
9/30/2018	29,585	2,099	2,215	2,946	N/A
6/30/2018	29,066	2,031	1,822	2,455	N/A
3/31/2018	28,519	1,895	N/A	1,985	N/A
12/31/2017	27,832	1,780	N/A	1,661	N/A
9/30/2017	27,911	1,740	N/A	1,009	N/A
6/30/2017	27,227	1,665	N/A	612	N/A
3/31/2017	26,363	1,556	N/A	1,085	N/A
12/31/2016	25,380	1,447	N/A	1,347	N/A
9/30/2016	24,491	1,365	N/A	957	N/A
6/30/2016	23,588	1,253	N/A	796	N/A
3/31/2016	22,682	1,188	N/A	387	N/A
12/31/2015	21,727	1,097	N/A	659	N/A
9/30/2015	20,923	1,136	N/A	545	N/A
6/30/2015	20,220	1,034	N/A	1,144	N/A
3/31/2015	19,656	899	N/A	857	N/A
12/31/2014	18,947	757	N/A	741	N/A
9/30/2014	18,208	655	N/A	1,349	N/A
6/30/2014	17,724	631	N/A	624	N/A
3/31/2014	17,237	617	N/A	395	N/A
12/31/2013	16,718	575	N/A	477	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 000963 'nin tahmini kazanç büyümesi (yıllık 13.5% ) tasarruf oranının ( 2.9% ) üzerindedir.

Kazançlar ve Piyasa: 000963 şirketinin kazançlarının (yıllık 13.5% ) CN pazarından (yıllık 23.2% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: 000963 şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: 000963 şirketinin gelirinin (yıllık 8.1% ) CN pazarından (yıllık 13.2% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 000963 şirketinin gelirinin (yıllık 8.1% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 000963 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 16.4 %).

Huadong Medicine Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Huadong Medicine Co., Ltd (SZSE:000963) Yearly Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Price target increased to CN¥49.08

Price target increased to CN¥43.06

Price target decreased to CN¥38.92

Price target increased to CN¥45.53

Price target increased to CN¥38.24

Recent updates

Huadong Medicine Co., Ltd to Report Q3, 2024 Results on Oct 25, 2024

Investor sentiment improves as stock rises 18%

There Are Reasons To Feel Uneasy About Huadong Medicine's (SZSE:000963) Returns On Capital

Huadong Medicine Co., Ltd Announces Interim Profit Distribution Plan to Be Implemented on A Shares for the Year 2024, Payable on 20 September 2024

Huadong Medicine Co., Ltd. Announces Interim Dividend for the First Half of 2024

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Earnings Working Against Huadong Medicine Co., Ltd's (SZSE:000963) Share Price

Huadong Medicine Co., Ltd to Report First Half, 2024 Results on Aug 16, 2024

Huadong Medicine (SZSE:000963) Seems To Use Debt Rather Sparingly

There Are Reasons To Feel Uneasy About Huadong Medicine's (SZSE:000963) Returns On Capital

Huadong Medicine Co., Ltd Approves Cash Dividend

High number of new directors

Huadong Medicine Co., Ltd (SZSE:000963) Yearly Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Huadong Medicine Co., Ltd, Annual General Meeting, May 08, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Market Cool On Huadong Medicine Co., Ltd's (SZSE:000963) Earnings

Huadong Medicine Co., Ltd to Report Q1, 2024 Results on Apr 26, 2024

Is Huadong Medicine (SZSE:000963) A Risky Investment?

Huadong Medicine Co., Ltd to Report Fiscal Year 2023 Results on Apr 18, 2024

Huadong Medicine's Unit, Partners to Invest in Pharmaceutical Firm

Huadong Medicine's Unit, Partners to Invest in Pharmaceutical Firm

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Huadong Medicine Co., Ltd to Report First Half, 2023 Results on Aug 16, 2023

Huadong Medicine Co., Ltd Implements Final Profit Distribution Plan of A Shares for 2022, Payable on 14 June 2023

Huadong Medicine Co., Ltd Approves Cash Dividend for 2022

Full year 2022 earnings: EPS misses analyst expectations

Price target increased to CN¥49.08

Third quarter 2022 earnings: EPS misses analyst expectations

Investor sentiment improved over the past week

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased to CN¥43.06

Huadong Medicine Co., Ltd Approves Board Appointments

Huadong Medicine Co., Ltd, Annual General Meeting, Jun 01, 2022

Price target decreased to CN¥38.92

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Third quarter 2021 earnings released: EPS CN¥0.34 (vs CN¥0.38 in 3Q 2020)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS CN¥0.31 (vs CN¥0.33 in 2Q 2020)

Price target increased to CN¥45.53

Investor sentiment deteriorated over the past week

Huadong Medicine Co., Ltd Announces 2020 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 09 June 2021

Huadong Medicine Co., Ltd Announces Dividend for 2020

Investor sentiment deteriorated over the past week

Price target increased to CN¥38.24

Full year 2020 earnings released: EPS CN¥1.61 (vs CN¥1.61 in FY 2019)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Huadong Medicine Co., Ltd to Report Fiscal Year 2020 Results on Apr 21, 2021

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Price target raised to CN¥34.09

New 90-day low: CN¥26.05

Price target raised to CN¥33.50

Market bids up stock over the past week

New 90-day high: CN¥30.35

Third-quarter earnings released: Revenue and earnings miss expectations

Third quarter earnings released

Huadong Medicine Co., Ltd to Report Q3, 2020 Results on Oct 27, 2020

First half earnings released

Huadong Medicine Co., Ltd to Report First Half, 2020 Results on Aug 28, 2020

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin